Specific usage and dosage of acotinib/acalatinib

Acalabrutinib/Acalabrutinib (Acalabrutinib): is a new Bruton’s tyrosine kinase (BTK) inhibitor, mainly It is used to treat malignant tumors derived from B cells such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Developed by AstraZeneca, this drug is a new generation of BTK-targeted drugs after ibrutinib. It has higher target selectivity and reduces interference with non-target enzymes. Therefore, it has relatively few side effects in actual use, especially the adverse effects on the heart and gastrointestinal system. According to the global mainstream recommendation plan,

The usual usage of acotinib is 100 mg orally twice daily, usually 12 hours apart. The drug is administered in capsule form and should be swallowed whole without crushing, chewing or dissolving. It is recommended to take it on an empty stomach or with a low-fat diet to optimize its absorption and utilization in the body. If the patient misses a dose and it is more than 6 hours before the next dose, the patient can take it immediately. However, if it is less than 6 hours, he should skip it directly to avoid double taking. In addition, patients should avoid co-administration with strong CYP3A enzyme inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampicin) while taking acotinib, as this may significantly change the concentration of the drug in the body, affect efficacy or increase the risk of toxicity.

For patients with hepatic or renal insufficiency, there are currently no clear guidelines for dosage adjustment, but the medication needs to be taken under close supervision by a physician. During treatment, you should also be alert to adverse reactions such as bleeding, infection, headache, etc. If symptoms are severe, you should inform your doctor in time to evaluate whether to adjust the dose or suspend medication. As a highly selective targeted drug, acotinib provides a new treatment option for many patients who are resistant or intolerant to first-generation BTK inhibitors. In clinical application, acotinib is considered a more precise and better-tolerated treatment option.

Reference materials:https://www.calquence.com/